Theravance (THRX) 9.81 $THRX The 3 Most Important

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Theravance (THRX) 9.81 $THRX

The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 29, 1:02PM CST
Image source: GlaxoSmithKline. Among Big Pharma, no drugmaker in particular has been given a reprieve from the patent cliff. However, U.K.-based GlaxoSmithKline was just late to the party. Whereas most of GlaxoSmithKline's peers dealt with...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07), NVS: 82.72 (-0.35)

Theravance Inc. Stock Was Up 14% in December -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jan 10, 11:07AM CST
What : Shares of  Theravance Inc , a healthcare royalty company, put up another greatly monthly performance as the company's stock moved more than 14% higher during the month of December, according to data from  S&P Capital IQ . So...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07)

Theravance, Inc. Announces Name Change to Innoviva, Inc.
Marketwired - Fri Jan 08, 7:00AM CST
Theravance, Inc. (NASDAQ: THRX), a healthcare-focused asset management company, today announced that it changed its name to Innoviva, Inc., effective January 7, 2016. In addition to Innoviva's new name, the company has also unveiled a new corporate identity and website, available at www.inva.com.
INVA: 12.60 (-0.44), THRX: 9.81 (+0.04)

Will 2016 Be GlaxoSmithKline plc's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 04, 8:59AM CST
Image source: GlaxoSmithKline. Although the broad-based market was relatively flat this year, some investors are certainly happy to put 2015 in the rearview mirror. Shareholders of U.K.-based pharma giant GlaxoSmithKline are a good example. A...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07), NVS: 82.72 (-0.35)

Theravance Up 17.4% Since SmarTrend Uptrend Call (THRX)
Comtex SmarTrend(R) - Thu Dec 31, 2:10PM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 17.38% as of today's recent price of $10.67.
THRX: 9.81 (+0.04)

SmarTrend Watching for Potential Pullback in Shares of Theravance After 3.82% Gain
Comtex SmarTrend(R) - Mon Dec 28, 5:23PM CST
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $10.41 to a high of $10.91. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $10.75 on volume of 825,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THRX: 9.81 (+0.04)

The Best GlaxoSmithKline plc Headlines in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 28, 1:34PM CST
Image source: GlaxoSmithKline via Flickr. As the year comes to a close, the only certainty shareholders of U.K.-based pharmaceutical giant GlaxoSmithKline have known this year is constant uncertainty. It seems like there isn't a Big Pharma...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07), NVS: 82.72 (-0.35)

Theravance Shares Up 16.3% Since SmarTrend's Buy Recommendation (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:26AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)

Uptrend Call Working As Theravance Stock Rises 16.3% (THRX)
Comtex SmarTrend(R) - Thu Dec 24, 10:22AM CST
SmarTrend identified an Uptrend for Theravance (NASDAQ:THRX) on October 5th, 2015 at $9.09. In approximately 3 months, Theravance has returned 16.28% as of today's recent price of $10.57.
THRX: 9.81 (+0.04)

Will GlaxoSmithKline plc Raise Its Dividend in 2016?
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 21, 9:39AM CST
Image source: GlaxoSmithKline.  It's been a rough 2015 for Big Pharma stocks, which have been whipsawed for much of the year, but the one solace that most large drug developers continue to offer their investors is an above-average dividend yield...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07), NVS: 82.72 (-0.35)

GlaxoSmithKline plc's Best Drug in 2015
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 15, 7:21AM CST
Image source: GlaxoSmithKline via Flickr. It's been something of a rough year for U.K.-based pharmaceutical giant GlaxoSmithKline . Through Dec. 9 the Market Vectors Pharmaceutical ETF has been flat for the year, but shareholders of...
GILD: 80.24 (-0.22), THRX: 9.81 (+0.04), GSK: 45.32 (+0.07)

Theravance, Inc. Announces Preliminary Results of Tender Offer
Marketwired - Wed Dec 02, 6:00AM CST
Theravance, Inc. (NASDAQ: THRX) today announced the preliminary results of its "modified Dutch auction" tender offer, which expired at 5:00 P.M., New York City time, on Tuesday, December 1, 2015. Theravance intends to continue implementing the previously announced share repurchase plan through open market purchases, and may also repurchase shares through private transactions, exchange offers, additional tender offers or other means.
THRX: 9.81 (+0.04)

5 Things GlaxoSmithKline PLC Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 19, 8:16AM CST
Image source: GlaxoSmithKline.  Three weeks ago, U.K.-based pharmaceutical giant GlaxoSmithKline reported its third-quarter results and handily clobbered Wall Street's profit projections, to the surprise of many. For those who may have missed...
THRX: 9.81 (+0.04), GSK: 45.32 (+0.07), NVS: 82.72 (-0.35)

Why Theravance Inc. Vaulted 15% Higher in October
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:51AM CST
What: Shares of Theravance , a healthcare royalty company, bounced back from their huge downward move in September , moving more than 15% higher during the month of October, according to data from S&P Capital IQ . So what:  Investors...
THRX: 9.81 (+0.04)

Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 04, 3:06PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in November 2015:
THRX: 9.81 (+0.04)

Theravance announces launch of self-tender offer for up to USD75m of common stock
M2 - Mon Nov 02, 5:04AM CST
Bio-pharmaceutical company Theravance (NASDAQ:THRX) revealed on Friday that it has commenced a "modified Dutch auction" tender offer for up to USD75m of its common stock.
THRX: 9.81 (+0.04)

Theravance, Inc. Announces Commencement of Self-Tender Offer for up to $75,000,000 of Its Common Stock
Marketwired - Fri Oct 30, 5:00AM CDT
Theravance, Inc. (NASDAQ: THRX) today announced that it is commencing its previously announced "modified Dutch auction" tender offer for up to $75,000,000 of its common stock at a price per share not less than $8.50 and not greater than $9.25. The tender offer will expire at 5:00 P.M., New York City time, on Tuesday, December 1, 2015, unless extended by the company. Tenders of shares must be made on or prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer, in each case, in accordance with the procedures described in the tender offer materials.
THRX: 9.81 (+0.04)

Theravance's Q3 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Thu Oct 29, 12:19PM CDT
Theravance (THRX) reported a third quarter loss of 4 cents per share along with total revenues of $13.6 million.
AZN: 33.87 (+0.03), AMAG: 26.16 (-0.86), GSK: 45.32 (+0.07), THRX: 9.81 (+0.04)

Why Shares of Theravance Inc Dropped 49% in September
Brian Feroldi, The Motley Fool - Motley Fool - Sun Oct 25, 2:03PM CDT
Shares of Theravance , a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC released disappointing clinical news. Are the shares a buy...
IBB: 289.71 (-4.36), THRX: 9.81 (+0.04), GSK: 45.32 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading